Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.
Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S. Shiffman ML, et al. Among authors: parise er. Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. Hepatol Int. 2014. PMID: 26202757
[13C-methacetin breath test in chronic hepatitis C liver disease].
Oliveira AC, Reber M, Lanzoni V, Ferraz ML, Parise ER. Oliveira AC, et al. Among authors: parise er. Arq Gastroenterol. 2006 Jan-Mar;43(1):41-4. doi: 10.1590/s0004-28032006000100011. Epub 2006 May 8. Arq Gastroenterol. 2006. PMID: 16699617 Free article. Portuguese.
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group. Parise E, et al. Braz J Infect Dis. 2006 Feb;10(1):11-6. doi: 10.1590/s1413-86702006000100003. Epub 2006 Jun 2. Braz J Infect Dis. 2006. PMID: 16767309 Free article.
Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H Jr, Tatsch F. Pessôa MG, et al. Among authors: parise er. Ann Hepatol. 2012 Jan-Feb;11(1):52-61. Ann Hepatol. 2012. PMID: 22166561 Free article. Clinical Trial.
Latin American Association for the Study of the Liver recommendations on treatment of hepatitis C.
Méndez-Sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-Ferraz ML, Soza A, Mendes-Correa MC, Chávez-Tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-Avila JF, Contreras F, Moraes-Coelho HS, Parise ER, Bessone F, Uribe M; Latin American Association for the Study of the Liver. Méndez-Sánchez N, et al. Among authors: parise er. Ann Hepatol. 2014 Aug;13 Suppl 2:s4-66. Ann Hepatol. 2014. PMID: 25185535 Free article. Review. No abstract available.
Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
Passos-Castilho AM, Lo Turco E, Ferraz ML, Matos C, Silva I, Parise E, Pilau E, Gozzo F, Granato C. Passos-Castilho AM, et al. J Gastrointestin Liver Dis. 2015 Mar;24(1):43-9. doi: 10.15403/jgld.2014.1121.pas. J Gastrointestin Liver Dis. 2015. PMID: 25822433 Free article.
81 results